Abstract: Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I or Formula II.

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Abstract: Provided is a pharmaceutical composition including an active pharmaceutical ingredient, a toll-like receptor (TLR) agonist, a stimulator of interferon genes (STING) agonist, and a pharmaceutically acceptable carrier. Also provided are a method for inducing immune response and a method for treating or preventing cancer or an infectious disease, including administering an effective amount of the pharmaceutical composition to a subject in need thereof.

Abstract: The present invention relates to a new type of metabolizable flower-like gold nanodandelion (GND), which possesses features: (1) large scale green synthesis with high monodispersity and a circa 100% yield; (2) cellular/physiological degradability; (3) precision control of the shape, petal number and size; (4) highly efficient radiotheranostics encompassing better enhanced CT contrast and pronounced x-ray induced ROS generation than conventional spherical AuNP.

Abstract: An electronic device and a method for diagnosing heart state based on electrocardiogram (ECG) are provided. An ECG file is obtained, and the ECG file is in a first file format and includes a plurality of potential traces of a plurality of leads. The ECG file is converted to a second file format to obtain electrocardiogram data corresponding to multiple leads. Each potential trace relative to time in the ECG file is converted to the ECG data of each lead. Integrated ECG data associated with the leads is generated based on the ECG data of the plurality of leads through the zero-padding operation and the stacking operation. A diagnostic result of heart status is generated based on the integrated ECG data and a deep learning model.

Abstract: The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

Abstract: Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

Abstract: The present application relates to one or more fusion proteins, comprising a structural domain of SARS-CoV-2 S(Spike) protein. The present application also relates to an immunogenic composition comprising the fusion protein and an application thereof.

Abstract: Disclosed are compounds of formula (I) as follows: in which each of R1, R2, R3, R4, R5, L1, W, and Het is defined herein. Also provides are a method of inhibiting prostaglandin reductase 2 (“PTGR2”) using such a compound and a pharmaceutical composition containing same.

Abstract: Provided is a method for preventing or treating urological chronic pelvic pain syndrome (UCPPS) in a subject that includes administering an effective amount of cerium oxide nanoparticles (CeNPs) to the subject. Also provided is a method for preventing or treating an UCPPS in a subject that includes administering to the subject a pharmaceutical composition comprising an effective amount of the CeNPs and a pharmaceutically acceptable carrier thereof.

Abstract: Isoindoline compounds and their pharmaceutical compositions. Also provided are methods of treating a Cisd2-insufficiency associated disorder and protecting against doxorubicin-induced cardiotoxicity.

Abstract: The disclosure provides a therapeutic method for preventing, ameliorating and/or treating Alzheimer's disease in a subject in need of such treatment. The therapeutic method comprises administrating to said subject a pharmaceutical combination comprising an effective amount of curcumin analog, TML-6 and an effective amount of an anti-A beta (A?) antibody.

Abstract: A construction method of ribosomal RNA database is provided, including the following steps: selecting a source of nucleic acid sequence database; performing normalization and homogenization on species classification rules; using AI technology for normalized classification and correction; selecting the kingdom to which the sequence species belongs; filtering out redundant sequences and sequences with inconsistent lengths; setting a threshold for unknown bases other than A, T, C or G, and excluding unknown bases that exceed the threshold; and excluding sequences with insufficient classification information.

Abstract: A feature selection method is provided, including: inputting a plurality of pieces of training data into a plurality of training models to perform selection in a plurality of features through each training model for obtaining multiple feature pools; sorting the features based on the number of times each feature is selected by the feature pools to obtain a feature ranking; and extracting a plurality of designated features from the features based on the feature ranking.

Abstract: A wearable ultrasonic therapeutic device controlled by a mobile electronic device is provided, which includes a mobile device, at least one ultrasonic probe module and a strap. The mobile device has a mobile device control interface for setting ultrasonic parameters and displaying an echo wave through a specific software interface of the mobile device. The ultrasonic probe module includes at least one ultrasonic transducer and a control circuit corresponding thereto. The ultrasonic transducer generates and receives an ultrasonic wave. The control circuit has the functions of generating/receiving signals, phase regulation, power amplification and matching. One end of the ultrasonic probe module is electrically connected to the mobile device and the other end of the ultrasonic probe module is connected to the strap.

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Abstract: The present invention relates to a method for body weight control in a subject in need thereof, comprising administering an effective amount of a thiolated chitosan to the subject. In particular, the thiolated chitosan of the present invention comprises a plurality of thiol groups covalently bonded to a chitosan moiety thereof. The thiolated chitosan of the present invention can be orally administered, which is effective in slowing down body weight gain and has good biocompatibility.

Abstract: An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).

Abstract: Isolated antibodies that bind specifically to R-spondin 3 (RSPO3) are described. Also described herein are compositions containing the antibodies and methods of using the antibodies to treat cancer and detect RSPO3.

Abstract: A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is: ra(t,i,j)=1?exp{[H(t0)?H(t1)]Ca(t,i,j)} ra(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t0 is an age of one patient at a state of the disease i. t1 is an age of the patient after the period of time. t is an age between t0 and t1. H(t0) and H(t1) are hazards of the complication occurring at the age t0 and the age t1, respectively.